This article provides a comprehensive comparison of Ligand-Based Drug Design (LBDD) and Structure-Based Drug Design (SBDD) for researchers and drug development professionals.
This article provides a comprehensive overview of ligand-based drug design (LBDD), a fundamental computational approach in drug discovery used when the 3D structure of a biological target is unavailable.
This comprehensive review synthesizes current evidence and methodologies for evaluating the comparative effectiveness of drug classes on cardiovascular outcomes.
This article provides a comprehensive guide for researchers and drug development professionals on the critical process of validating Mixed Treatment Comparison (MTC) and Network Meta-Analysis (NMA) results against direct evidence.
This article provides a comprehensive synthesis of current evidence on the comparative efficacy and safety of pharmacologic options for Type 2 Diabetes, tailored for researchers, scientists, and drug development professionals.
This article provides a comprehensive guide for researchers and drug development professionals on validating Real-World Evidence (RWE) for Health Technology Assessment (HTA).
This article provides a comprehensive methodological comparison of direct and indirect treatment effects, tailored for researchers, scientists, and drug development professionals.
This article provides a comprehensive analysis of the frameworks and methodologies for comparing the safety and efficacy of new drugs against the standard of care, tailored for researchers, scientists, and...
Network meta-analysis (NMA) has become an indispensable tool for comparative effectiveness research, enabling the evaluation of therapeutic equivalence and hierarchy among multiple interventions in the absence of head-to-head trials.
This article provides researchers, scientists, and drug development professionals with a comprehensive framework for assessing the validity of Indirect Treatment Comparisons (ITCs) anchored by a common comparator.